Day: March 8, 2024

Key Operating MetricsDollars in thousands, except per share data. Dollar and percentage changes may not recalculate due to rounding. Charts may not be to scale.ROGERS, Ark., March 08, 2024 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today reported financial results for the third quarter ended January 31, 2024. Third Quarter Key Highlights (Q3 FY24 vs. Q3 FY23, unless otherwise noted)Completed implementation of updated loan origination system (LOS) Q3 revenue was $299.6 million, down 7.9% Total collections increased 9.3% Allowance for credit loss adjusted to 25.74%, down sequentially 30 bps Net charge-offs as a % of average finance receivables were 6.8% vs. 5.9%, down sequentially 40 bps Loss per share $1.34 vs. $0.23 diluted earnings per share Entered into a strategic...

INDIANAPOLIS, March 08, 2024 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the first fiscal quarter ended January 31, 2024. Hurco recorded a net loss of $1,648,000, or $0.25 per diluted share, for the first quarter of fiscal year 2024, compared to net income of $1,330,000, or $0.20 per diluted share, for the corresponding period in fiscal year 2023. Sales and service fees for the first quarter of fiscal year 2024 were $45,059,000, a decrease of $9,623,000, or 18%, compared to the corresponding prior year period, and included a favorable currency impact of $779,000, or 1%, when translating foreign sales to U.S. dollars for financial reporting purposes. Greg Volovic, Chief Executive Officer, stated, “We were disappointed with first quarter results but are continuing to invest in the future growth...

ELK GROVE VILLAGE, Ill., March 08, 2024 (GLOBE NEWSWIRE) — SigmaTron International, Inc. (NASDAQ: SGMA), an electronic manufacturing services company (the “Company”), today reported revenues and earnings for the fiscal quarter ended January 31, 2024. Revenues from continuing operations increased $3.2 million, or 3 percent, to $95.9 million in the third quarter of fiscal 2024, compared to $92.7 million for the same quarter in the prior year. Net income from continuing operations for the third quarter ended January 31, 2024, was $0.6 million, compared to $2.7 million for the same quarter in the prior year. Diluted income per share from continuing operations for the quarter ended January 31, 2024 was $0.10, compared to $0.44 income per share for the same quarter in the prior year. For the nine months ended January 31, 2024, revenues...

FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “Ocuphire had a successful 2023, with notable achievements on the regulatory and development fronts, paving the way for further progress in the year ahead,” said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire. “Our strategic focus is on the advancement of our retina pipeline, and we are preparing our late-stage clinical program to progress APX3330 in diabetic retinopathy (“DR”). We believe APX3330 may represent a promising oral treatment...

Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or before September 2024OV888 (GV101) is progressing on-track in a Phase 1, double-blind, multiple-ascending dose trial; a higher dose cohort has been added and no serious adverse events have been observedFeedback from a pre-IND session with the FDA supports potential initiation of a Phase 2 study of OV888 (GV101) in the second half of 2024Phase 1 study with OV329 continues to progress; data expected in the second half of 2024Cash, cash equivalents and marketable securities of $105.8 million as of December 31, 2023; expected to support runway into first half of 2026NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) — Ovid Therapeutics...

Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related to our growing royalty base and the achievement of certain development milestones during 2023 Added third commercial asset to XOMA’s portfolio with the acquisition of economic interests in DSUVIA® (sufentanil sublingual tablet) in January 2024 Closed 2023 with two partners’ New Drug Applications (NDA) submitted to the U.S. Food and Drug Administration (FDA) EMERYVILLE, Calif., March 08, 2024 (GLOBE NEWSWIRE) —  XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its fourth quarter and full year 2023 financial results and highlighted portfolio activities expected to drive long-term shareholder value. “Over the...